Posted by Michael Wonder on 09 Nov 2018
Lilly snaps up regulatory 'fast pass' for bargain price
2 November 2018 - Priority review vouchers used to be highly sought: back in 2015, for example, AbbVie paid United Therapeutics $350 million for one.
While they still are valuable commodities, the price has fallen dramatically as supply has increased, with $80 million the apparent going rate if this and a recent deal between Ultragenyx and Kyowa Hakko Kirin deal are anything to go by.
Lilly hasn't stated how it will use the PRV, which can shorten review times for New Drug Applications from 10 to six months. The money will be a boost for Siga Technologies, which currently has a market cap of about $380 million, and a focus on products aimed at emerging pathogens and biodefense threats. TPOXX is its only approved product, and it has further smallpox antiviral candidates in its pipeline.
